MET and neoplasm: ,20 In the SAVANNAH study, MET-IHC 90 or higher (3+ staining in ≥90% tumor cells) or MET FISH10+ (GCN ≥ 10) were associated with the survival benefits of combining osimertinib and savolitinib (ORR = 49%, mPFS = 7.1 mo).27